{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:53:38Z","timestamp":1789016018104,"version":"build-2803163510"},"reference-count":60,"publisher":"Impact Journals, LLC","issue":"25","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,4,3]]},"DOI":"10.18632\/oncotarget.24878","type":"journal-article","created":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T10:21:41Z","timestamp":1522664501000},"page":"17735-17755","source":"Crossref","is-referenced-by-count":5,"title":["Clinical importance of the EMSY gene expression and polymorphisms in ovarian cancer"],"prefix":"10.18632","volume":"9","author":[{"given":"Agnieszka","family":"Dansonka-Mieszkowska","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz M.","family":"Szafron","sequence":"additional","affiliation":[{"name":"Department of Immunology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Moes-Sosnowska","sequence":"additional","affiliation":[{"name":"Department of Immunology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Kulinczak","sequence":"additional","affiliation":[{"name":"Department of Immunology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Balcerak","sequence":"additional","affiliation":[{"name":"Department of Molecular and Translational Oncology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bozena","family":"Konopka","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Kulesza","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Budzilowska","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyna","family":"Lukasik","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urszula","family":"Piekarska","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona K.","family":"Rzepecka","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Parada","sequence":"additional","affiliation":[{"name":"Department of Immunology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Zub","sequence":"additional","affiliation":[{"name":"Department of Molecular and Translational Oncology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pienkowska-Grela","sequence":"additional","affiliation":[{"name":"Cytogenetics Laboratory, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radoslaw","family":"Madry","sequence":"additional","affiliation":[{"name":"Department of Oncology, Poznan University of Medical Sciences, Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan K.","family":"Siwicki","sequence":"additional","affiliation":[{"name":"Department of Immunology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Kupryjanczyk","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2018,4,3]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.seminoncol.2007.03.012","article-title":"The management of recurrent ovarian cancer","volume":"34","author":"Markman","year":"2007","journal-title":"Semin Oncol"},{"key":"2","doi-asserted-by":"publisher","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Sessa","year":"2013","journal-title":"Ann Oncol"},{"key":"3","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.3390\/cancers7040897","article-title":"Paclitaxel through the ages of anticancer therapy: exploring its role in Chemoresistance and Radiation Therapy","volume":"7","author":"Chen","year":"2015","journal-title":"Cancers"},{"key":"4","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Kroemer","year":"2012","journal-title":"Oncogene"},{"key":"5","doi-asserted-by":"publisher","first-page":"43598","DOI":"10.18632\/oncotarget.18419","article-title":"Olaparib and somatic BRCA mutations","volume":"8","author":"Kaye","year":"2017","journal-title":"Oncotarget"},{"key":"6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.critrevonc.2016.02.014","article-title":"Ovarian cancer: status of homologous recombination pathway as a predictor of drug response","volume":"101","author":"Labidi-Galy","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"7","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0092-8674(03)00930-9","article-title":"EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer","volume":"115","author":"Chia","year":"2003","journal-title":"Cell"},{"key":"8","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1056\/NEJMcibr033528","article-title":"A novel BRCA2-binding protein and breast and ovarian tumorigenesis","volume":"350","author":"King","year":"2004","journal-title":"N Engl J Med"},{"key":"9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nm0204-127","article-title":"EMSY, a BRCA-2 partner in crime","volume":"10","author":"Livingston","year":"2004","journal-title":"Nat Med"},{"key":"10","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jmb.2005.05.047","article-title":"Crystal structure of the ENT domain of human EMSY","volume":"350","author":"Doherty","year":"2005","journal-title":"J Mol Biol"},{"key":"11","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1093\/jnci\/dji254","article-title":"Genomic instability of human mammary epithelial cells overexpressing a truncated form of EMSY","volume":"97","author":"Eaves","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00438-011-0612-5","article-title":"EMSY overexpression disrupts the BRCA2\/RAD51 pathway in the DNA-damage response: implications for chromosomal instability\/recombination syndromes as checkpoint diseases","volume":"285","author":"Belmaaza","year":"2011","journal-title":"Mol Genet Genomics"},{"key":"13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/path.2944","article-title":"Functional characterization of EMSY gene amplification in human cancers","volume":"225","author":"Reis-Filho","year":"2011","journal-title":"J Pathol"},{"key":"14","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.str.2006.01.007","article-title":"Crystal structure of the HP1-emsy complex reveals an unusual mode of HP1 binding","volume":"14","author":"Xu","year":"2006","journal-title":"Structure"},{"key":"15","doi-asserted-by":"publisher","first-page":"17222","DOI":"10.1073\/pnas.0705629104","article-title":"The basic helix-loop\u2013helix domain of maize R links transcriptional regulation and histone modifications by recruitment of an EMSY-related factor","volume":"104","author":"Grotewold","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"16","doi-asserted-by":"publisher","first-page":"E613","DOI":"10.1073\/pnas.1115029109","article-title":"The protein kinase AKT1 regulates the interferon response through phosphorylation of the transcriptional repressor EMSY","volume":"109","author":"Tsichlis","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.4161\/trns.21904","article-title":"AKT1, EMSY, BRCA2 and type I IFN signaling: a novel arm of the ifn response","volume":"3","author":"Tsichlis","year":"2012","journal-title":"Transcription"},{"key":"18","doi-asserted-by":"publisher","first-page":"7542","DOI":"10.1074\/jbc.M805872200","article-title":"Identification and characterization of a novel nuclear protein complex involved in nuclear hormone receptor-mediated gene regulation","volume":"284","author":"Samuels","year":"2009","journal-title":"J Biol Chem"},{"key":"19","doi-asserted-by":"publisher","first-page":"5061","DOI":"10.1007\/s13277-013-1584-3","article-title":"The function of EMSY in cancer development","volume":"35","author":"Yang","year":"2014","journal-title":"Tumour Biol"},{"key":"20","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.1158\/1078-0432.CCR-03-0410","article-title":"Amplification of the BRCA2 pathway gene emsy in sporadic breast cancer is related to negative outcome","volume":"10","author":"Rodriguez","year":"2004","journal-title":"Clin Cancer Res"},{"key":"21","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/BF03345613","article-title":"Absence of allelic imbalance involving emsy, CAPN5, and PAK1 genes in papillary thyroid carcinoma","volume":"31","author":"Ramirez-Lorca","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"22","first-page":"343","article-title":"Amplification of EMSY gene in a subset of sporadic pancreatic adenocarcinomas","volume":"1","author":"Goggins","year":"2008","journal-title":"Int J Clin Exp Pathol"},{"key":"23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11033-010-0116-0","article-title":"Expression of EMSY gene in sporadic ovarian cancer","volume":"38","author":"Buyru","year":"2011","journal-title":"Mol Biol Rep"},{"key":"24","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ygyno.2005.08.026","article-title":"Amplification of EMSY, a novel oncogene on 11Q13, in high grade ovarian surface epithelial carcinomas","volume":"100","author":"Huntsman","year":"2006","journal-title":"Gynecol Oncol"},{"key":"25","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1007\/s13277-014-2944-3","article-title":"EMSY promoted the growth and migration of ovarian cancer cells","volume":"36","author":"Wang","year":"2015","journal-title":"Tumor Biol"},{"key":"26","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1158\/1535-7163.MCT-12-0813","article-title":"Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer","volume":"12","author":"Velculescu","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"27","doi-asserted-by":"publisher","first-page":"e72162","DOI":"10.1371\/journal.pone.0072162","article-title":"Type-specific cell line models for type-specific ovarian cancer research","volume":"8","author":"Huntsman","year":"2013","journal-title":"PLS One"},{"key":"28","doi-asserted-by":"publisher","first-page":"e103988","DOI":"10.1371\/journal.pone.0103988","article-title":"Ovarian cancer cell line panel (OCCP): clinical importance ofmorphological subtypes","volume":"9","author":"Helleman","year":"2014","journal-title":"PLoS One"},{"key":"29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/gcc.20549","article-title":"Amplification of 11q13 in ovarian carcinoma","volume":"47","author":"Huntsman","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"30","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1186\/s13058-014-0467-x","article-title":"A novel mechanism of regulation of the anti-metastatic miR-31 by EMSY in breast cancer","volume":"16","author":"O\u2019Connor","year":"2014","journal-title":"Breast Cancer Res"},{"key":"31","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.molcel.2014.01.029","article-title":"The breast cancer oncogene EMSY represses transcription of antimetastatic microRNA miR-31","volume":"53","author":"Kouzarides","year":"2014","journal-title":"Mol Cell"},{"key":"32","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.cell.2009.03.047","article-title":"A pleiotropically acting microrna, miR-31, inhibits breast cancer metastasis","volume":"137","author":"Weinberg","year":"2009","journal-title":"Cell"},{"key":"33","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1158\/0008-5472.CAN-09-3875","article-title":"Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers","volume":"70","author":"Anderson","year":"2010","journal-title":"Cancer Res"},{"key":"34","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13048-015-0186-7","article-title":"MicroRNA-200c and microRNA-31 regulate proliferation, colony formation, migration and invasion in serous ovarian cancer","volume":"8","author":"Mokhtar","year":"2015","journal-title":"J Ovarian Res"},{"key":"35","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1038\/oncsis.2013.3","article-title":"Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET","volume":"2","author":"Sakuragi","year":"2013","journal-title":"Oncogenesis"},{"key":"36","doi-asserted-by":"publisher","first-page":"294","DOI":"10.18632\/oncoscience.143","article-title":"P18\/stathmin1 is regulated by miR-31 in ovarian cancer in response to taxane","volume":"2","author":"Sakuragi","year":"2015","journal-title":"Oncoscience"},{"key":"37","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009209","article-title":"MET: a critical player in tumorigenesis and therapeutic target","volume":"5","author":"Vande Woude","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"38","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1002\/cncr.24282","article-title":"Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel","volume":"115","author":"Katsaros","year":"2009","journal-title":"Cancer"},{"key":"39","doi-asserted-by":"publisher","first-page":"14004","DOI":"10.1073\/pnas.0504195102","article-title":"Amplification of a chromatin remodeling gene, RSF-1\/HBXAP, in ovarian carcinoma","volume":"102","author":"Wang","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"40","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1158\/0008-5472.CAN-08-3602","article-title":"Functional analysis of 11q13.5 amplicon identifies RSF-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer","volume":"69","author":"Shih","year":"2009","journal-title":"Cancer Res"},{"key":"41","doi-asserted-by":"publisher","first-page":"13792","DOI":"10.18632\/oncotarget.14637","article-title":"The EMSY threonine 207 phospho-site is required for EMSYdriven suppression of DNA damage repair","volume":"8","author":"Levine","year":"2017","journal-title":"Oncotarget"},{"key":"42","doi-asserted-by":"publisher","first-page":"e113169","DOI":"10.1371\/journal.pone.0113169","article-title":"A genomic instability score in discriminating nonequivalent outcomes of BRCA1\/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapy.","volume":"9","author":"Hao","year":"2014","journal-title":"PLoS One"},{"key":"43","doi-asserted-by":"publisher","first-page":"R219","DOI":"10.1530\/ERC-15-0237","article-title":"The state-of-play and future of platinum drugs","volume":"22","author":"Wheate","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1471-2407-5-81","article-title":"Common variation in EMSY and risk of breast and ovarian cancer: a case-control study using hapmap tagging SNPs","volume":"5","author":"Pharoah","year":"2005","journal-title":"BMC Cancer"},{"key":"45","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1186\/s12885-017-3488-x","article-title":"Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families","volume":"17","author":"Schleutker","year":"2017","journal-title":"BMC Cancer"},{"key":"46","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/ijc.25754","article-title":"Identification of an aggressive prostate cancer predisposing variant at 11q13","volume":"129","author":"Schleutker","year":"2011","journal-title":"Int J Cancer"},{"key":"47","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1016\/j.ejca.2013.06.006","article-title":"Fine mapping of 11q13.5 identifies regions associated with prostate cancer and prostate cancer death","volume":"49","author":"Schleutker","year":"2013","journal-title":"Eur J Cancer"},{"key":"48","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2006-7-s1-s12","article-title":"AceView: a comprehensive cDNA-supported gene and transcripts annotation","volume":"7","author":"Thierry-Mieg","year":"2006","journal-title":"Genome Biol"},{"key":"49","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.1038\/ncomms6593","article-title":"GWAS identifies four novel eosinophilic esophagitis loci","volume":"5","author":"Hakonarson","year":"2014","journal-title":"Nat Commun"},{"key":"50","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Hertzog","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"Davidson","year":"1996","journal-title":"N Engl J Med"},{"key":"52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int J Gynecol Obstet"},{"key":"53","unstructured":"Kurman. Weltgesundheitsorganisation, International Agency for Research on Cancer, editors. WHO classification of tumours of female reproductive organs: [\u2026 reflects the views of a working group that convened for a consensus and editorial meeting at the International Agency for Research on Cancer (IARC), Lyon, June 13-15, 2013]. 4. ed. Lyon: International Agency for Research on Cancer; 2014. 307 p."},{"key":"54","first-page":"795","article-title":"Histologic and nuclear grading and stromal reactions as indices for prognosis in ovarian cancer","volume":"121","author":"Kwon","year":"1975","journal-title":"Am J Obstet Gynecol"},{"key":"55","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Winkler","year":"1981","journal-title":"Cancer"},{"key":"56","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1006\/gyno.1994.1354","article-title":"Salvage chemotherapy for epithelial ovarian carcinoma","volume":"55","author":"Trimble","year":"1994","journal-title":"Gynecol Oncol"},{"key":"57","article-title":"Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes","volume":"3","author":"Speleman","year":"2002","journal-title":"Genome Biol"},{"key":"58","doi-asserted-by":"publisher","first-page":"R19","DOI":"10.1186\/gb-2007-8-2-r19","article-title":"qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data","volume":"8","author":"Vandesompele","year":"2007","journal-title":"Genome Biol"},{"key":"59","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Schmittgen","year":"2001","journal-title":"Methods"},{"key":"60","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/bimj.200810443","article-title":"The performance of risk prediction models","volume":"50","author":"Schumacher","year":"2008","journal-title":"Biom J"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.24878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T15:37:49Z","timestamp":1589038669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.24878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,3]]},"references-count":60,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2018,4,3]]}},"alternative-id":["24878","29707144"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.24878","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,3]]}}}